BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $330,139 | -16.9% | 4,850 | -0.3% | 0.01% | -14.3% |
| Q2 2023 | $397,293 | +101.8% | 4,867 | +83.5% | 0.01% | +75.0% |
| Q1 2023 | $196,826 | -7.5% | 2,653 | +3.3% | 0.00% | -33.3% |
| Q4 2022 | $212,836 | +106.6% | 2,568 | +609.4% | 0.01% | +100.0% |
| Q3 2022 | $103,000 | +267.9% | 362 | +352.5% | 0.00% | +200.0% |
| Q2 2022 | $28,000 | -98.1% | 80 | -97.6% | 0.00% | -97.4% |
| Q1 2022 | $1,466,000 | +498.4% | 3,386 | +614.3% | 0.04% | +533.3% |
| Q4 2021 | $245,000 | -2.8% | 474 | -9.0% | 0.01% | -14.3% |
| Q3 2021 | $252,000 | -50.0% | 521 | -50.2% | 0.01% | -50.0% |
| Q2 2021 | $504,000 | -59.6% | 1,046 | -68.0% | 0.01% | -64.1% |
| Q1 2021 | $1,248,000 | +860.0% | 3,267 | +700.7% | 0.04% | +680.0% |
| Q4 2020 | $130,000 | -73.2% | 408 | -79.2% | 0.01% | -75.0% |
| Q3 2020 | $485,000 | -14.3% | 1,959 | -8.7% | 0.02% | -44.4% |
| Q2 2020 | $566,000 | -60.8% | 2,145 | -71.8% | 0.04% | -63.3% |
| Q1 2020 | $1,444,000 | +496.7% | 7,617 | +591.8% | 0.10% | +444.4% |
| Q4 2019 | $242,000 | +830.8% | 1,101 | +715.6% | 0.02% | +800.0% |
| Q3 2019 | $26,000 | -79.4% | 135 | -77.6% | 0.00% | -80.0% |
| Q2 2019 | $126,000 | – | 604 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |